Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins

References

• Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM Howley PM, editors. Fields Virology. 5th ed. Philadelphia, USA: Lippincot Williams & Wilkins; 2007. p. 1691-740.
   Google Scholar
• Webster RG, Govorkova EA. Continuing challenges in influenza. Ann NY Acad Sci. 2014;1323:115–39.
   PubMed Web of Science ®Google Scholar
• Abt M, de Jonge J, Laue M, et al. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content. Vaccine. 2011;29:5153–62.
   PubMed Web of Science ®Google Scholar
• Cox NJ, Hickling J, Jones R, et al. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014. Vaccine. 2015; 33(48):6503-10.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Op Virol. 2013;3:521–30.
   PubMed Web of Science ®Google Scholar
• Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015; 349(6254):1301-6.10.1126/science.aac7263
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015; 21(9):1065-70.10.1038/nm.3927
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev. 2015;14:167–82.
   Google Scholar
• McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983;309:13–17.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19:1305–12.
   PubMed Web of Science ®Google Scholar
• Lee LY, Ha do LA, Simmons C, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest. 2008;118:3478–90.10.1111/j.1365-2362.1990.tb01797.x
   PubMed Web of Science ®Google Scholar
• van de Sandt CE, Kreijtz JH, de Mutsert G, et al. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol. 2014;88:1684–93.
   PubMed Web of Science ®Google Scholar
• Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of cross-protective immunity against influenza. Vaccine. 2015;33:500–6.
   PubMed Web of Science ®Google Scholar
• Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. Annu Rev Immunol. 2009;27:61–82.
   PubMed Web of Science ®Google Scholar
• de Bree GJ, van Leeuwen EM, Out TA, et al. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med. 2005;202:1433–42.
   PubMed Web of Science ®Google Scholar
• Purwar R, Campbell J, Murphy G, et al. Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS ONE. 2011;6:e16245.10.1371/journal.pone.0016245
   Google Scholar
• Vitelli A, Quirion MR, Lo CY, et al. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo pan paniscus. PLoS ONE. 2013;8(3):e55435.10.1371/journal.pone.0055435
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant Simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther. 2014;22(3):668–74.10.1038/mt.2013.284
   PubMed Web of Science ®Google Scholar
• Wang W, Li R, Deng Y, et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA- and vaccinia virus-based universal influenza A virus vaccines in mice. Clin Vacc Immunol. 2015;22(6):618–30.10.1128/CVI.00091-15
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55:19–25.
   PubMed Web of Science ®Google Scholar
• Boyd AC, Ruiz-Hernandez R, Peroval MY, et al. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine 2013;31:670–5.
   PubMed Web of Science ®Google Scholar
• Hessel A, Savidis-Dacho H, Coulibaly S, et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS ONE. 2014;9(2):e88340.10.1371/journal.pone.0088340
   PubMed Web of Science ®Google Scholar
• Altenburg AF, Kreijtz JH, de Vries RD, et al. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014;6:2735–61.
   PubMed Web of Science ®Google Scholar
• Mullarkey CE, Boyd A, van Laarhoven A, et al. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine. Eur J Immunol. 2013;43:1940–52.
   PubMed Web of Science ®Google Scholar
• Di Mario G, Garulli B, Sciaraffia E, et al. A heat-inactivated H7N3 vaccine induces cross-reactive cellular immunity in HLA-A2.1 transgenic mice. Virol J. 2016;13:56
   PubMed Web of Science ®Google Scholar
• Di Lullo G, Soprana E, Panigada M, et al. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified Vaccinia virus Ankara vaccine production for human use. J Virol Meth. 2010;163:195–204.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2011. Global influenza surveillance network. Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
   Google Scholar
• Newberg MH, Smith DH, Haertel SB, et al. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules. J Immunol. 1996;156:2473–80.
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Oseroff C, Sidney J, et al. Human memory CTL response specific for influenza A virus is broad and multispecific. Human Immunol. 2000;61:438–52.
   PubMed Web of Science ®Google Scholar
• Assarsson E, Bui HH, Sidney J, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008;2:12241–51.
   Web of Science ®Google Scholar
• Alexander J, Bilsel P, del Guercio MF, et al. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Human Immunol. 2010;71:468–74.
   PubMed Web of Science ®Google Scholar
• Townsend AR, Rothbard J, Gotch FM, et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986;44:959–68.
   PubMed Web of Science ®Google Scholar
• Vitiello A, Yuan L, Chesnut RW, et al. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol. 1996;157:5555–5562.
   PubMed Web of Science ®Google Scholar
• Belz GT, Xie W, Doherty PC. Diversity of epitope and cytokine profiles for primary and secondary influenza A virus-specific CD8+ T cell responses. J Immunol. 2001;166:4627–33.
   PubMed Web of Science ®Google Scholar
• Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Op Biotechnol. 2004;15:506–12.
   PubMed Web of Science ®Google Scholar
• Gilbert SC. Clinical development of modified Vaccinia virus Ankara vaccines. Vaccine. 2013;31:4241–46.
   PubMed Web of Science ®Google Scholar
• Oukka M, Manuguerra JC, Livaditis N, et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol. 1996;157:3039–45.
   PubMed Web of Science ®Google Scholar
• Holtappels R, Simon CO, Munks MW, et al. Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination. J Virol. 2008;82:5781–96.
   PubMed Web of Science ®Google Scholar
• LaMere MW, Lam H, Moquin A, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol. 2011;186:4331–9.
   PubMed Web of Science ®Google Scholar
• Plotnicky H, Cyblat-Chanal D, Aubry JP, et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/Kb transgenic mice. Virology. 2003;309:320–9.
   PubMed Web of Science ®Google Scholar
• Matsui M, Kohyama S, Suda T, et al. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun. 2010;391:1494–9.
   PubMed Web of Science ®Google Scholar
• Suda T, Kawano M, Nogi Y, et al. The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus. Antiviral Research. 2011;91:252–8.
   PubMed Web of Science ®Google Scholar
• Carrasco M, Amorim MA, Digard P. Lipid raft-dependent targeting of the influenza A virus nucleoprotein to the apical plasma membrane. Traffic. 2004;5:979–92.
   PubMed Web of Science ®Google Scholar
• Ruigrok RW, Barge A, Durrer P, et al. Membrane interaction of influenza virus M1 protein. Virology. 2000;267:289–98.
   PubMed Web of Science ®Google Scholar
• Heesters BA, van der Poel CE, Das A, et al. Antigen presentation to B cells. Trend Immunol. 2016; 37(12):844–54.
   PubMed Web of Science ®Google Scholar